Outcome

This pilot study provides promising evidence that hyperbaric oxygen therapy (HBO2) may serve as a beneficial adjunctive or alternative treatment for rheumatoid arthritis. Using the RAMRIS criteria all nine patients exhibited no radiologic progression of erosions synovitis or bone marrow edema at both three- and six-month MRI scans.

Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune condition that leads to painful joint inflammation and progressive damage. This pilot study investigated the potential of hyperbaric oxygen therapy (HBOT) as a novel treatment option for RA. Nine patients diagnosed with RA underwent 30 HBOT sessions over six to ten weeks with magnetic resonance imaging (MRI) scans taken at baseline three months and six months. The MRIs were analyzed using the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) criteria which measure inflammation and joint damage. Remarkably all participants showed no progression in radiologic markers such as erosions synovitis or bone marrow edema during the follow-up periods. These findings suggest that HBOT might serve as a promising adjunct or alternative therapy to help manage RA providing hope for improvements in disease activity and joint health without relying solely on traditional disease-modifying drugs.

Results

Nine patients diagnosed with rheumatoid arthritis underwent hyperbaric oxygen therapy (HBOT) receiving 30 treatments over six to ten weeks. Magnetic resonance imaging (MRI) was employed at baseline three months and six months using the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) criteria to assess inflammation and joint damage.

Notably the MRI results showed no progression in key radiologic markers—erosions synovitis or bone marrow edema—across all participants at both three- and six-month follow-ups. This lack of progression suggests that HBOT has a stabilizing effect on the disease process within this timeframe indicating its potential utility as a complement or alternative to conventional disease-modifying therapies in the management of rheumatoid arthritis.

The findings underscore the potential of HBOT to offer therapeutic benefits without further joint degradation providing a promising avenue for patients seeking alternative or adjunctive treatments for their condition.

Conclusion

In conclusion this pilot study provides compelling evidence that hyperbaric oxygen therapy (HBOT) may offer a beneficial adjunctive or alternative treatment for rheumatoid arthritis (RA). The application of HBOT showed no radiologic progression of erosions synovitis or bone marrow edema in any of the nine patients over a six-month follow-up period as assessed using the RAMRIS criteria. These findings highlight the potential of HBOT to halt the progression of joint inflammation and damage associated with RA presenting a promising therapeutic avenue that extends beyond conventional disease-modifying drugs. This could be especially valuable for patients with limited treatment options or those who experience adverse effects from traditional therapies. Future research with larger cohorts and extended follow-up durations is recommended to further substantiate these preliminary findings and explore the broader applicability of HBOT in RA management.